BDBM241779 US9409917, 104::US9409917, 105::US9409917, 76::US9409917, 77::US9409917, 85::US9409917, 86

SMILES Clc1cc2CCC(NC(=O)C3COc4ncccc34)c2c(Cl)c1

InChI Key InChIKey=KWFRKVWOJFLNAF-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 241779   

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 4.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 9.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 20.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 164nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 5.10E+3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent